TrialMolecular cancer therapeutics2024

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0.

Joseph Markowitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.